Latest Commercialization News

Clarity Pharmaceuticals has completed a $203 million institutional placement at a premium, bolstering its cash reserves to nearly $288 million and positioning the company to advance pivotal clinical trials and commercial preparations for its cancer-fighting radiopharmaceuticals.

Centaurus Metals reports strong value engineering results for its Jaguar Nickel Sulphide Project, confirming a 15-year mine life and first quartile costs, while advancing exploration at Boi Novo and Jambreiro iron ore projects.

Latrobe Magnesium Limited has extended its Pilot Project Licence with EPA Victoria until February 2027, paving the way to resume magnesium oxide production at its Hazelwood North site in August 2025.

ClearVue Technologies has appointed Douglas Hunt as its permanent Global CEO, unveiling a refreshed leadership team focused on scaling sales, manufacturing, and product innovation. The new executives have agreed to sub-market pay until the share price hits 35 cents, signaling strong alignment with shareholder interests.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.

Adriatic Metals reported a 23% rise in silver equivalent production in Q2 2025, driven by a 50% increase in ore milled, while revising full-year guidance lower due to operational constraints. The company also declared commercial production and agreed to a recommended acquisition by Dundee Precious Metals.

Iron Road Ltd has secured its key mining lease through 2026 and entered a strategic farm-in agreement targeting heavy mineral sands, navigating a tough iron ore investment climate and evolving green energy partnerships.

Charger Metals NL reported steady progress in its June 2025 quarterly activities, advancing lithium exploration at the Lake Johnston Project in Western Australia with funding support from Rio Tinto Exploration. The company awaits further drilling permits to continue testing promising targets.

Wide Open Agriculture reports a remarkable 243% jump in cash receipts driven by soaring lupin protein sales and secures a strategic foothold in China through an exclusive distribution deal.

Botanix Pharmaceuticals reports a strong commercial ramp-up for Sofdra™, with net revenue jumping from $0.7 million to $4.3 million in one quarter, supported by a $40 million capital raise and a $30 million debt facility.

Tamboran Resources appoints Chairman Dick Stoneburner as interim CEO following Joel Riddle’s departure, while adding two seasoned energy executives to its board as it advances gas production plans in the Beetaloo Basin.

Artrya has launched its AI-powered Salix Coronary Anatomy platform in the U.S. and submitted its Coronary Plaque module for FDA clearance, marking a key step in its commercial expansion. A new five-year contract with Tanner Health signals the start of U.S. revenues.